Envision Pharma Group’s Post

Unlocking the potential of oncology assets isn't just about groundbreaking science – it's about asking the right questions from day one. The commercialization of oncology products presents unique challenges due to the complex nature of cancer treatment landscapes, evolving standards of care, and the specific needs of patients, healthcare providers, and payers. Understanding where a product fits within these landscapes, navigating regulatory approval paths, and strategically planning patient support and engagement are crucial for a successful launch. As the market for oncology therapies evolves rapidly, it's essential to differentiate your asset and maximize its value proposition. Early and strategic questioning can guide informed decision-making, streamline the commercialization process, and ultimately lead to better patient outcomes.

Visit https://lnkd.in/e3Vc2zUF to read the latest Amplity Health article which details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care. #oncologyexpertise #biomarkerstesting #strategicleadership #solutionspartner

A recap of ESMO 2023: Let's revisit some of the significant and groundbreaking research presented at last month's ESMO conference in Madrid, Spain #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma

Research reveals that ~64% of potentially eligible patients are not benefiting from precision oncology therapies. As a solutions provider committed to improving the landscape of personalized medicine, we recognize the urgency of addressing clinical practice gaps. Visit https://lnkd.in/e3Vc2zUF to read our article which details the challenges pharmaceutical companies commonly face when integrating predictive biomarker testing into clinical care.

A Recap of ESMO 2023: Let's take a closer look at some of the notable and pioneering research unveiled during the ESMO conference held last month in Madrid, Spain. #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma

Reflecting on ESMO 2023, we at RAS have put together some of the important and very interesting research that was presented. Let us take a look back #esmo23 #oncology #competitiveintelligence #researchanddevelopment #cancercare #oncologyresearch #pharma

A recap from ESMO 2023 #esmo23 #raslss #oncology #oncologyresearch #competitiveintelligence #conferences #healthcare #rarediseases #cancerresearch #pharmaceutical #pharma

We attended the EMSO 2023 congress in Oct, at Madrid, during which we had the opportunity to learn about some of the recent advances in the field of cancer research, and also connect with some great minds! This year, >30,000 people attended the congress in person from >150 countries. Some of the "hot" topics that garnered a lot of attention were ADCs (antibody-drug conjugates) with several data readouts in late-breaking sessions such as 302/KEYNOTE-A39, TROPION-Breast01, DESTINY-PanTumor 01 etc. These molecules are anticipated to set new therapeutic standards. In addition to ADCs, lung cancer also took center stage during the conference with >25 sessions. Below is a crisp summary of the most notable topics that we captured during ESMO 2023 At RAS, we provide comprehensive conference coverage support across multiple therapeutic areas. If you would like to know more about our conference services or get hold of our conference reports, do reach out to us! Please like and share if you found the summary useful and comment below if you'd like us to send you a sample report. #oncology #cancerresearch #cancer #researchanddevelopment #conference #medicalconference #oncologyresearch #raslss #consultingservice #esmo2023 #esmo23

Novartis' Pluvicto spurs radiopharma mergers. Market set to reach $25B, with Novartis at the forefront. However, Big Pharma faces competition from other targeted therapies. #Novartis #Pluvicto #radiopharmaceuticals #Elililly #BMS #BristolMyersSquibb #mergersandacquisitions #cancer #RBCCapitalMarkets #targetedtherapy #oncology #ISPOR #ISPORUS

📢 Presenting Sidvim Regulatory Digest – January 2024 Edition! 📰   Stay updated on the latest Pharma regulatory changes with our concise summary. This week we cover the topic of " Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics " 💊   Stay ahead of the game and stay informed with Sidvim Lifesciences Regulatory Digest. #PharmaRegulation #Oncodrugs